Medicine details

ImageDiavix
NameDiavix
DosageTablet
Generic NameLamivudine + Zidovudine
Classes Antiviral Agent
Antiviral Combination
Antiinfective Agent
Diseases
CompanyBeximco Pharmaceuticals Ltd.

Drug Package Details

Strength150 mg + 300 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack10
Price per pack450.00
Cost per pack396.00
Package unit10 tabs strip
Price per unit45.00
Cost per unit39.60
Discount0
Coupon
Remarks

Lamivudine + Zidovudine

Lamivudine + Zidovudine is a combination of two nucleoside reverse transcriptase inhibitor. Both Lamivudine & Zidovudine are nucleoside analogs which are incorporated to the viral DNA during replication and inhibit the process terminating viral replication. 

Lamivudine + Zidovudine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 

  • Adults and Adolescents weighing greater than or equal to 30 kg: 1 tablet orally twice daily.
  • Pediatrics weighing greater than or equal to 30 kg: 1 tablet orally twice daily.
  • Because Lamivudine + Zidovudine is a fixed-dose tablet and cannot be dose adjusted, Lamivudine + Zidovudine is not recommended in patients requiring dosage adjustment or with hepatic impairment or experiencing dose-limiting adverse reactions.

The most common reported adverse reactions in adults were-

  • headache
  • nausea
  • malaise
  • fatigue
  • nasal signs and symptoms
  • diarrhea
  • cough
  • Hematologic Toxicity: The use of zidovudine, a component of Lamivudine + Zidovudine, has been linked to hematologic toxicity, including neutropenia and anemia.
  • Myopathy: Symptomatic myopathy associated with prolonged use of zidovudine. 
  • Exacerbations of Hepatitis B: Lactic Acidosis and Severe Hepatomegaly with Steatosis: The use of nucleoside analogues has been linked to lactic acidosis and severe hepatomegaly with steatosis, including fatal cases.
  • Patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have stopped taking lamivudine, a component of Lamivudine + Zidovudine, have experienced severe acute exacerbations of hepatitis B. In these patients, closely monitor hepatic function and, if necessary, initiate anti-hepatitis B treatment. 
  • In HIV-1/HCV co-infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin, hepatic decompensation, some fatal, has occurred. Discontinue lamivudine and zidovudine tablets as needed, and consider reducing or discontinuing interferon alfa, ribavirin, or both.

     

  • Anemia has been reported to worsen in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Ribavirin and zidovudine should not be taken together.

     

  • In patients with a history of pancreatitis or other significant risk factors for pancreatitis, use with caution. As clinically indicated, discontinue treatment.

     

  • In patients receiving combination antiretroviral therapy, immune reconstitution syndrome and redistribution/accumulation of body fat have been reported.

Contraindication

Contraindicated in patients with a previous hypersensitivity reaction to-